Post-Cycle Therapy (PCT) is a standard topic in research logs that involve hormonal compounds. This article explains, at a high level, why it is discussed, what the published research literature actually examines, and how the commonly referenced compounds are studied. It is written as laboratory and educational reference material, not as guidance for human use.

Important: The compounds described below are supplied strictly for in-vitro and research applications. They are not approved medicines, have not been evaluated by the MHRA, EMA, or FDA for the uses discussed, and nothing here is medical advice, a dosing protocol, or a promise of any outcome.

What is post-cycle therapy (PCT)?

In research contexts, “post-cycle therapy” refers to the set of compounds and concepts studied for supporting a return toward hormonal baseline after a period of exposure to androgenic or other hormonally active substances. The term originates from the observation that many performance-related compounds alter the body’s own endocrine signalling. PCT is therefore discussed as a recovery-focused phase rather than a performance phase, and it is one of the most frequently referenced ideas in hormonal research literature.

Why does the HPTA need to recover after a cycle?

The hypothalamic–pituitary–testicular axis (HPTA) is a feedback loop. The hypothalamus releases GnRH, the pituitary responds with luteinising hormone (LH) and follicle-stimulating hormone (FSH), and these signal endogenous testosterone production. When exogenous androgens are present, the loop senses sufficiency and downregulates GnRH, LH, and FSH. Research describes the resulting low-output state as anabolic steroid-induced hypogonadism (ASIH). Because the axis is suppressed rather than destroyed, the literature focuses on how, and how quickly, signalling resumes once exogenous input stops.

What does the research show about recovery?

A 2023 scoping review in Endocrine Connections (Solanki et al.) examined physical, psychological, and biochemical recovery from ASIH. It reported that recovery timelines vary with age and the degree and duration of prior androgen exposure: gonadotropin recovery is often described over roughly three to six months, with testosterone and spermatogenesis frequently recovering over months, though longer or incomplete recovery is documented in some longer-term users. The review underlines that outcomes are individual and not guaranteed, which is precisely why the recovery phase receives so much attention in the literature.

What is enclomiphene and how is it studied?

Enclomiphene citrate is a selective estrogen receptor modulator (SERM) and the trans-isomer of clomiphene. By occupying estrogen receptors at the hypothalamus and pituitary, it has been studied for its effect on the feedback loop — specifically whether it can raise LH and FSH and, in turn, endogenous testosterone. In phase II research in men with secondary hypogonadism (Wiehle et al., 2013; Wiehle et al., 2014), enclomiphene citrate was associated with increased serum testosterone and gonadotropins while preserving sperm parameters, in contrast to exogenous testosterone gel. These findings are reported as research outcomes in study populations, not as instructions or expected results for any individual.

How do SERMs differ from exogenous testosterone in the research?

This is a comparative distinction that appears throughout the literature. SERMs are studied as “restoration” agents that work upstream on the axis, whereas exogenous androgens act as direct replacement that can further suppress endogenous signalling. The table below summarises how the two approaches are characterised in published studies. It is descriptive of research findings only.

Is enclomiphene a licensed medicine in the UK?

No. Enclomiphene is not an approved medicine in the UK and has not been authorised by the MHRA for the uses discussed in research. Materials supplied for laboratory work are research-grade reference compounds, not pharmaceuticals, and are not intended for human or veterinary use. Legal status, classification, and permitted handling can vary by jurisdiction and over time, so anyone working with these materials is responsible for confirming the applicable rules in their own location.

What is commonly referenced in PCT research discussions?

Research PCT discussions frequently mention SERMs such as enclomiphene alongside dedicated PCT reference formulas. The relevant research-grade materials in our catalogue include PCT and Enclomiphene. These are listed for educational and laboratory reference only, with no dosing guidance and no human-use claims.

How is research quality and purity verified?

As with everything we carry, these research materials are third-party tested. Independent analysis supports identity and purity claims, and certificates of analysis (COAs) can be requested for specific batches. See the Lab Tests page for verified batches and COA requests. Reliable characterisation matters in research because reproducibility depends on knowing exactly what a sample contains.

Research references

• Wiehle RD, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. BJU International. 2013;112(8):1188–1200. doi:10.1111/bju.12363
• Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertility and Sterility. 2014;102(3):720–727. doi:10.1016/j.fertnstert.2014.06.004
• Solanki P, Eu B, Smith J, Allan C, Lee K. Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocrine Connections. 2023;12(12):e230358. doi:10.1530/EC-23-0358

Research-use disclaimer: For laboratory and educational research purposes only. Not for human or veterinary consumption. These compounds are not approved medicines and have not been evaluated by the MHRA, EMA, or FDA for the uses discussed. Nothing here is medical advice.